This inventor holds 54 USPTO granted patents and 2 published patent applications, plus 9 CIPO patents and 17 EPO patents, primarily in Ethynyl Derivatives (CPC class C07D). Top assignee: Hoffmann-La Roche Inc.. Active years: 1992-2017.
Inventors with similar research interests:
Location History:
- Rheinfelden, CH (1992 - 2013)
- Basel, CH (2013 - 2016)
- Aadorf, CH (2017)
Company Filing History:
Years Active: 1992-2017
Areas of Expertise:
Title: Heinz Stadler: Innovator in Ethynyl Derivatives
Introduction: Heinz Stadler, based in Basel, Switzerland, is a notable inventor with an impressive portfolio of 54 patents. His innovative contributions, particularly in the realm of pharmaceuticals, have significantly advanced treatment options for various neurological conditions.
Latest Patents: Among his latest patents, Stadler has developed ethynyl derivatives that serve as metabotropic glutamate receptor antagonists. These compounds function as negative allosteric modulators and have the potential to be utilized in the treatment of several conditions, including anxiety, pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
Career Highlights: Throughout his career at Hoffmann-La Roche Inc., Stadler has demonstrated a commitment to innovation and scientific advancement. His extensive research and development efforts have not only contributed to the company's success but also improved therapeutic options for patients around the world.
Collaborations: Stadler works alongside esteemed colleagues, including Eric Vieira and Georg Jaeschke, reinforcing a collaborative environment that fosters groundbreaking research and innovative solutions in the pharmaceutical industry.
Conclusion: Heinz Stadler stands out as a significant contributor to the field of pharmaceutical innovation. His work on ethynyl derivatives showcases his expertise and dedication to improving health outcomes, solidifying his position as a leading inventor in the industry.